{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:54:00Z","timestamp":1780433640951,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s40263-020-00716-6","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T19:02:45Z","timestamp":1585335765000},"page":"535-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab"],"prefix":"10.1007","volume":"34","author":[{"given":"Eleonora","family":"Sgarlata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Grazia","family":"Chisari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Millefiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-0846","authenticated-orcid":false,"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"key":"716_CR1","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"716_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","volume":"17","author":"EO Major","year":"2018","unstructured":"Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018;17:467\u201380.","journal-title":"Lancet Neurol."},{"key":"716_CR3","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870\u201380.","journal-title":"N Engl J Med"},{"key":"716_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"16","author":"P-R Ho","year":"2017","unstructured":"Ho P-R, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925\u201333.","journal-title":"Lancet Neurol."},{"key":"716_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295\u2013303.","journal-title":"Ann Neurol"},{"key":"716_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","volume":"57","author":"P Lee","year":"2013","unstructured":"Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, et al. A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2013;57:141\u20136.","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol."},{"key":"716_CR7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802\u201312.","journal-title":"Ann Neurol"},{"key":"716_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler Houndmills Basingstoke Engl. 2012;18:143\u201352.","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"key":"716_CR9","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","volume":"3","author":"N Schwab","year":"2016","unstructured":"Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, G\u00f6bel K, et al. Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflammation. 2016;3:e195.","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"key":"716_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/jnnp-2016-315106.113","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87:117\u201325.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"716_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.msard.2014.04.003","volume":"3","author":"F Sangalli","year":"2014","unstructured":"Sangalli F, Moiola L, Ferr\u00e8 L, Radaelli M, Barcella V, Rodegher M, et al. Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. Mult Scler Relat Disord. 2014;3:520\u20136.","journal-title":"Mult Scler Relat Disord."},{"key":"716_CR12","doi-asserted-by":"crossref","unstructured":"Scarpazza C, De Rossi N, Tabiadon G, Turrini MV, Gerevini S, Capra R. Four cases of natalizumab-related PML: a less severe course in extended interval dosing? Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2019;.","DOI":"10.1007\/s10072-019-03959-4"},{"key":"716_CR13","unstructured":"Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis. - PubMed - NCBI [Internet]. [cited 2019 Mar 6]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30410486."},{"key":"716_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292\u2013302.","journal-title":"Ann Neurol"},{"key":"716_CR15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/ene.13355","volume":"24","author":"ZLE van Kempen","year":"2017","unstructured":"van Kempen ZLE, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, et al. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients. Eur J Neurol. 2017;24:1196\u20139.","journal-title":"Eur J Neurol"},{"key":"716_CR16","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00415-017-8643-4","volume":"264","author":"J Peters","year":"2017","unstructured":"Peters J, Williamson E. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time. J Neurol. 2017;264:2409\u201312.","journal-title":"J Neurol"},{"key":"716_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1177\/1352458513505353","volume":"20","author":"O Outteryck","year":"2014","unstructured":"Outteryck O, Z\u00e9phir H, Salleron J, Ongagna J-C, Etxeberria A, Collongues N, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler Houndmills Basingstoke Engl. 2014;20:822\u20139.","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"key":"716_CR18","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1177\/1352458515599681","volume":"21","author":"J Raffel","year":"2015","unstructured":"Raffel J, Gafson AR, Malik O, Nicholas R. Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler Houndmills Basingstoke Engl. 2015;21:1833\u20138.","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"key":"716_CR19","first-page":"257","volume":"45","author":"I Correia","year":"2017","unstructured":"Correia I, Jesus-Ribeiro J, Batista S, Martins AI, Nunes C, Mac\u00e1rio MC, et al. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population. J Clin Neurosci Off J Neurosurg Soc Australas. 2017;45:257\u201360.","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas."},{"key":"716_CR20","doi-asserted-by":"crossref","unstructured":"Paz SPC, Branco L, Pereira MA de C, Spessotto C, Fragoso YD. Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica. Epidemiol Health. 2018;40:e2018001.","DOI":"10.4178\/epih.e2018001"},{"key":"716_CR21","doi-asserted-by":"publisher","first-page":"839719","DOI":"10.1155\/2013\/839719","volume":"2013","author":"A Bellizzi","year":"2013","unstructured":"Bellizzi A, Anzivino E, Rodio DM, Palamara AT, Nencioni L, Pietropaolo V. New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. Clin Dev Immunol. 2013;2013:839719.","journal-title":"Clin Dev Immunol"},{"key":"716_CR22","doi-asserted-by":"crossref","unstructured":"Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL a. N, et al. High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol. 2016;23:1079\u201385.","DOI":"10.1111\/ene.12988"},{"key":"716_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/1352458517728814","volume":"24","author":"N Schwab","year":"2018","unstructured":"Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, et al. Anti-JCV serology during natalizumab treatment: review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters. Mult Scler Houndmills Basingstoke Engl. 2018;24:563\u201373.","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"key":"716_CR24","unstructured":"JCV serology in time: 3 years of follow-up. - PubMed - NCBI [Internet]. [cited 2019 Aug 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=CV+serology+in+time%3A+3+years+of+follow-up."},{"key":"716_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2018;24:96\u2013120.","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"key":"716_CR26","doi-asserted-by":"crossref","unstructured":"Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, et al. Natalizumab in Multiple Sclerosis: Long-Term Management. Int J Mol Sci [Internet]. 2017 [cited 2019 Jan 16];18. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5454853\/.","DOI":"10.3390\/ijms18050940"},{"key":"716_CR27","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00415-018-8813-z","volume":"265","author":"S Aoyama","year":"2018","unstructured":"Aoyama S, Mori M, Uzawa A, Uchida T, Masuda H, Ohtani R, et al. Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration. J Neurol. 2018;265:1145\u201350.","journal-title":"J Neurol"},{"key":"716_CR28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883\u201397.","journal-title":"Nat Rev Drug Discov."},{"key":"716_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.msard.2019.06.016","volume":"34","author":"S Blumenfeld-Kan","year":"2019","unstructured":"Blumenfeld-Kan S, Staun-Ram E, Miller A. Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire. Mult Scler Relat Disord. 2019;34:29\u201337.","journal-title":"Mult Scler Relat Disord."},{"key":"716_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","volume":"8","author":"J Borchardt","year":"2016","unstructured":"Borchardt J, Berger JR. Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler Relat Disord. 2016;8:145\u201350.","journal-title":"Mult Scler Relat Disord."},{"key":"716_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1177\/1352458515607651","volume":"22","author":"N Schwab","year":"2016","unstructured":"Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, G\u00f6rlich D, Meinl I, et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler Houndmills Basingstoke Engl. 2016;22:1048\u201360.","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"key":"716_CR32","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1177\/1352458514556302","volume":"21","author":"M Delgado-Garc\u00eda","year":"2015","unstructured":"Delgado-Garc\u00eda M, Matesanz F, Alcina A, Fedetz M, Garc\u00eda-S\u00e1nchez MI, Ruiz-Pe\u00f1a JL, et al. A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands. Mult Scler Houndmills Basingstoke Engl. 2015;21:1104\u201311.","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"key":"716_CR33","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","volume":"93","author":"LZ Ryerson","year":"2019","unstructured":"Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93:e1452\u201362.","journal-title":"Neurology."},{"key":"716_CR34","doi-asserted-by":"crossref","unstructured":"Foley J, Gudesblatt M, Zarif M, Lathi E. Low Body Weight as a Potential Surrogate Risk Factor for Progressive Multifocal Leukoencephalopathy (P2.244). Neurology. 2014;82:P2.244.","DOI":"10.1212\/WNL.82.10_supplement.P2.244"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-020-00716-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:14:03Z","timestamp":1722644043000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-020-00716-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00716-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,27]]},"assertion":[{"value":"27 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was not fonded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eleonora Sgarlata declares there is no conflict of interest. Clara G. Chisari declares there is no conflict of interest. Emanuele D\u2019Amico declares there is no conflict of interest. Enrico Millefiorini received grants from Biogen, Merck Serono, Novartis Genzyme and Roche, consulting fees from Biogen, Merck Serono, Novartis Genzyme and Roche, travel support for congress participations from Biogen, Merck Serono, Novartis Genzyme and Roche; he also served as advisory board member for Bayer, Biogen, Merck Serono, Novartis Genzyme and Roche. Francesco Patti received grants from Almirall, Bayer, Biogen, Merck Serono, Novartis Genzyme, Teva and Roche, consulting fees from Biogen, Merck Serono, Novartis Genzyme and Roche, travel support for congress participations from Almirall, Biogen, Merck Serono, Novartis Genzyme, Teva and Roche; he also served as advisory board member for Almirall, Bayer, Biogen, Merck Serono, Novartis, Genzyme, Teva and Roche. He was also fonded by Pfizer and FISM for epidemiological studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study protocol was approved by the local Ethical Committee of the University of Catania (Catania 1).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each patient participating to the study signed an Informed Consent specifically designed for the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}